Nogami Yashiro, Kinoshita Manabu, Takase Bonpei, Ogata Yoshitaka, Saitoh Daizoh, Kikuchi Makoto, Ishihara Masayuki, Maehara Tadaaki
Department of Surgery, National Defense Medical College Research Institute, Tokorozawa, Japan.
Ann Surg. 2008 Aug;248(2):310-9. doi: 10.1097/SLA.0b013e3181820c80.
To investigate the efficacy of liposome-encapsulated hemoglobin (LHb) transfusion in rats undergoing lethal progressive hemodilution.
Unlike other acellular hemoglobin-based oxygen carriers, LHb has lipid bilayer membranes that are similar to mammalian red blood cells (RBCs), which prevent hemoglobin from having any direct contact with the blood components and the endothelium. Acellular hemoglobin has a high affinity for nitric oxide (NO), and because they are reported to behave as NO scavengers, acellular hemoglobin-based oxygen carriers could have pressor effects on the peripheral vessels. During a massive hemorrhage, acellular hemoglobin caused vasoconstriction could decrease peripheral perfusion, thereby leading to diminished oxygen delivery.
Rats were subjected to blood withdrawal (0.2 mL/min) with a simultaneous resuscitation using an isovolemic fluid transfusion that contained LHb, 5% albumin, or washed rat RBCs for 150 minutes (n = 15 in each group).
All rats transfused with LHb or RBCs were rescued from lethal progressive hemodilution, whereas none of the albumin-transfused rats survived. LHb did not affect the plasma NO metabolite levels, suggesting it was not a potent NO scavenger. LHb also improved hemodilution-induced metabolic acidosis, and reduced exaggerated neuroendocrine responses and injuries to the heart, liver, and kidney. It suppressed expression of hypoxia-inducible factor-1alpha in the liver and kidney, suggesting improvement of hypoxia at molecular response levels. However, neither transfused LHb nor RBCs improved the acute lung injury that occurs after progressive hemodilution.
LHb transfusion is effective in rescuing rats undergoing progressive hemodilution from lethal organ hypoxia without scavenging NO.
研究脂质体包裹血红蛋白(LHb)输注对经历致死性渐进性血液稀释大鼠的疗效。
与其他无细胞血红蛋白基氧载体不同,LHb具有与哺乳动物红细胞(RBC)相似的脂质双分子层膜,可防止血红蛋白与血液成分和内皮直接接触。无细胞血红蛋白对一氧化氮(NO)具有高亲和力,据报道它们可作为NO清除剂,基于无细胞血红蛋白的氧载体可能对外周血管产生升压作用。在大量出血期间,无细胞血红蛋白引起的血管收缩会减少外周灌注,从而导致氧输送减少。
对大鼠进行采血(0.2 mL/分钟),同时使用含有LHb、5%白蛋白或洗涤过的大鼠RBC的等容液体输注进行复苏,持续150分钟(每组n = 15)。
所有输注LHb或RBC的大鼠均从致死性渐进性血液稀释中获救,而输注白蛋白的大鼠无一存活。LHb不影响血浆NO代谢物水平,表明它不是一种有效的NO清除剂。LHb还改善了血液稀释引起的代谢性酸中毒,减少了过度的神经内分泌反应以及对心脏、肝脏和肾脏的损伤。它抑制了肝脏和肾脏中缺氧诱导因子-1α的表达,表明在分子反应水平上改善了缺氧情况。然而,输注的LHb和RBC均未改善渐进性血液稀释后发生的急性肺损伤。
LHb输注可有效挽救经历渐进性血液稀释的大鼠免于致死性器官缺氧,且不会清除NO。